Price Caps In Regeneron’s COVID Monoclonal Deal With HHS: Not A Precedent, But Enough For Bernie

 
• By Derrick Gingery
  
COVID-19 monoclonal antibody
Regeneron is developing a new monoclonal antibody for prevention of COVID-19 with its BARDA contract. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from R&D

More from Pink Sheet